KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Receivables - Other: 2011-2025

Historic Receivables - Other for Sarepta Therapeutics (SRPT) over the last 9 years, with Sep 2025 value amounting to $128.7 million.

  • Sarepta Therapeutics' Receivables - Other rose 93.83% to $128.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $128.7 million, marking a year-over-year increase of 93.83%. This contributed to the annual value of $34.6 million for FY2024, which is 16.11% up from last year.
  • According to the latest figures from Q3 2025, Sarepta Therapeutics' Receivables - Other is $128.7 million, which was up 75.58% from $73.3 million recorded in Q2 2025.
  • Sarepta Therapeutics' Receivables - Other's 5-year high stood at $128.7 million during Q3 2025, with a 5-year trough of $8,000 in Q4 2021.
  • Moreover, its 3-year median value for Receivables - Other was $35.4 million (2023), whereas its average is $51.3 million.
  • As far as peak fluctuations go, Sarepta Therapeutics' Receivables - Other plummeted by 99.98% in 2021, and later surged by 41,287.50% in 2022.
  • Quarterly analysis of 5 years shows Sarepta Therapeutics' Receivables - Other stood at $8,000 in 2021, then spiked by 41,287.50% to $3.3 million in 2022, then spiked by 800.03% to $29.8 million in 2023, then increased by 16.11% to $34.6 million in 2024, then spiked by 93.83% to $128.7 million in 2025.
  • Its Receivables - Other stands at $128.7 million for Q3 2025, versus $73.3 million for Q2 2025 and $55.2 million for Q1 2025.